Washington D.C. (January 19, 2016) – The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced that Rodger Currie will join the association as executive vice president for advocacy. He will lead federal, state and international government affairs and alliance development. Currie returns to PhRMA on February 1, 2016.
A recognized leader in government relations and health care, Currie has advocated on behalf of patient groups, physicians, hospitals and the life sciences industry. Currie most recently served as chief of government affairs at the American Psychiatric Association. He was also a partner at a D.C. law firm. For more than a decade, he worked in the pharmaceutical industry: at Amgen, Inc., Currie served as vice president, global government affairs, working for passage of the Biologics Price Competition and Innovation Act of 2009, which became law as part of the Affordable Care Act; and he was senior vice president for government affairs and law at PhRMA during the multi-year effort to pass and implement Medicare Part D.
“Rodger’s breadth of experience and proven track record of success will be an invaluable addition to the PhRMA team as we seek to improve patients’ access to care and foster the continued development of new treatments and cures for patients,” said Stephen J. Ubl, PhRMA president and CEO.
Currie has a long record of working across party lines and collaborating with stakeholders across health care. For more than 10 consecutive years, The Hill newspaper named him a top lobbyist.
“The work of this industry is a passion of mine, and I’m excited to be coming home to PhRMA to help Steve Ubl bring the strongest possible advocacy for patients, innovation and cures. Steve brings energy and vision to the work we do and I am enthusiastic about joining his team,” said Currie. “I look forward to working with PhRMA member companies and the broader health care community to create a climate that fosters investment in science and access to life-saving medicines.”
Prior to PhRMA, Currie served as majority health counsel to House Energy & Commerce Chairman Tom Bliley (R-VA). During that time, he was counsel of record on the development and passage of the FDA Modernization Act of 1997 and the Medicare, Medicaid and CHIP provisions of the Balanced Budget Act of 1997. Currie holds B.A. and J.D. degrees from Georgetown University.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $51.2 billion in 2014 alone.